EFFICACY OF DICLOFENAC SODIUM VERSUS SOMATOSTATIN FOR THE PREVENTION OF PANCREATITIS IN PATIENTS UNDERGOING ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY

Abstract

Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) is an endoscopic procedure performed with a side view scope that can be either diagnostic or therapeutic. Endoscopic procedure as with other medical procedures has both minor and major complications. The most common major complication of ERCP is pancreatitis, with a prevalence of 1% to 40%.

Aim: to assess the efficacy of diclofenac sodium versus somatostatin for prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP).

Methods: the present study was carried out as an interventional study on 75 patients with evidence of biliary obstruction accepted for ERCP, divided into 3 groups. Group I included 25 patients as control group, group II included 25 patients who were administered 100 mg of diclofenac sodium administered rectally 30 minutes before ERCP and group III included 25 patients who were administered a single bolus injection of 250 mcg somatostatin 30 minutes before ERCP and these groups were compared regarding efficacy of diclofenac sodium versus somatostatin for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Results: there was no statistically difference between the study groups as regards the occurrence of post-ERCP pancreatitis. The incidence of post-ERCP pancreatitis was 13.3%. Post-ERCP pancreatitis occurred in 5 cases (20%) of the first group, 2 cases (8%) of the second group, 3 cases (12%) of the third group. No risk factors for post-ERCP pancreatitis were statistically significant.

Conclusion: there was no statistically difference between the study groups as regards the occurrence of post-ERCP pancreatitis.